WeVote
Log In

Bill

Bill

SB 974

Maryland Medical Assistance Program and Health Insurance - Nonopioid Drugs for the Treatment of Pain

2025 Regular Session Introduced by Clarence Lam

SB 974 requires Maryland health insurers to prioritize nonopioid pain medications in coverage policies to reduce opioid dependence and addiction.

Hearing 2/26 at 1:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · SB 974

Legislative bill overview

SB 974 would modify Maryland's Medical Assistance Program and health insurance regulations to prioritize coverage of nonopioid medications for pain treatment. The bill appears designed to incentivize or mandate insurance coverage preferences for nonopioid alternatives to opioid painkillers across the state's Medicaid program and potentially private insurance.

Why is this important

The opioid crisis has caused tens of thousands of deaths and widespread addiction in Maryland and nationally, making pain management policy a significant public health issue. Insurance coverage decisions directly affect which medications patients can access affordably, potentially reducing opioid prescriptions while ensuring patients have effective pain management alternatives available.

Potential points of contention

  • Cost implications: Nonopioid alternatives (such as certain biologics or newer medications) may be more expensive than traditional opioids, potentially increasing insurance premiums or state Medicaid expenditures
  • Clinical appropriateness: Different pain conditions respond differently to different medications; mandatory nonopioid preferences could limit physician discretion in treating patients whose pain genuinely requires opioid management
  • Implementation scope: Unclear whether this applies only to Medicaid, private insurance, or both, and whether it creates hard restrictions or soft incentives through prior authorization requirements

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.